Published in Nat Rev Drug Discov on November 01, 2007
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet (2008) 4.69
High-resolution genetic mapping using the Mouse Diversity outbred population. Genetics (2012) 3.28
The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther (2011) 2.93
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86
Drug-induced long QT syndrome. Pharmacol Rev (2010) 2.55
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46
Genome-wide association studies in pharmacogenomics. Nat Rev Genet (2010) 2.14
Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology (2010) 1.51
A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet (2011) 1.48
Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation (2009) 1.41
Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics (2011) 1.34
Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study. PLoS Comput Biol (2011) 1.26
Predicting adverse drug reactions using publicly available PubChem BioAssay data. Clin Pharmacol Ther (2011) 1.24
Predicting adverse side effects of drugs. BMC Genomics (2011) 1.22
Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput Biol (2009) 1.18
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther (2014) 1.17
Electronic medical records as a tool in clinical pharmacology: opportunities and challenges. Clin Pharmacol Ther (2012) 1.15
Quantification of the clinical modifiers impacting high-density lipoprotein cholesterol in the community: Personalized Medicine Research Project. Prev Cardiol (2010) 1.14
Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. Prev Cardiol (2009) 1.11
In vitro platforms for evaluating liver toxicity. Exp Biol Med (Maywood) (2014) 1.11
SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res (2009) 1.10
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics (2010) 1.10
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother (2011) 1.07
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol (2011) 1.06
Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci (2010) 1.06
Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PLoS One (2013) 1.04
Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J (2012) 1.00
Pharmacogenomics of human ABC transporter ABCC11 (MRP8): potential risk of breast cancer and chemotherapy failure. Anticancer Agents Med Chem (2010) 0.99
Pluripotent stem cell-based cancer therapy: promise and challenges. Sci Transl Med (2012) 0.99
Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J (2015) 0.95
Legal update: living with the Genetic Information Nondiscrimination Act. Genet Med (2008) 0.90
Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicol Sci (2014) 0.90
Individualized medicine enabled by genomics in Saudi Arabia. BMC Med Genomics (2015) 0.87
Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events. Sci Rep (2016) 0.86
Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics (2012) 0.85
Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis. Nat Commun (2015) 0.85
Zebrafish as model organisms for studying drug-induced liver injury. Br J Clin Pharmacol (2014) 0.85
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. Pharmacogenomics J (2010) 0.85
Label-free drug discovery. Front Pharmacol (2014) 0.85
Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease. PLoS One (2014) 0.84
Drug-Induced Liver Injury: Pattern Recognition and Future Directions. Gut Liver (2016) 0.84
Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab (2009) 0.83
Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics. Clin Pharmacol Ther (2011) 0.83
Pharmacogenetics: potential role in the treatment of diabetes and obesity. Expert Opin Pharmacother (2008) 0.82
Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies. Technology (Singap World Sci) (2015) 0.81
Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf (2016) 0.80
Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. Comb Chem High Throughput Screen (2015) 0.80
Subtoxic Alterations in Hepatocyte-Derived Exosomes: An Early Step in Drug-Induced Liver Injury? Toxicol Sci (2016) 0.79
Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy. J Control Release (2015) 0.79
Drug-induced liver injury in older adults. Ther Adv Drug Saf (2010) 0.79
Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. Stem Cell Res Ther (2013) 0.78
Determining molecular predictors of adverse drug reactions with causality analysis based on structure learning. J Am Med Inform Assoc (2013) 0.78
Genealogical analysis as a new approach for the investigation of drug intolerance heritability. Eur J Hum Genet (2013) 0.77
A non-synonymous single nucleotide polymorphism in an OPRM1 splice variant is associated with fentanyl-induced emesis in women undergoing minor gynaecological surgery. PLoS One (2012) 0.77
Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov (2016) 0.77
Assessing the translatability of in vivo cardiotoxicity mechanisms to in vitro models using causal reasoning. BMC Pharmacol Toxicol (2013) 0.77
The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management. Breast Care (Basel) (2009) 0.77
Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury? Pharm Res (2016) 0.76
PharmGKB summary: very important pharmacogene information for RYR1. Pharmacogenet Genomics (2016) 0.75
Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin. Clin J Pain (2015) 0.75
Self-reported medication side effects in an older cohort living independently in the community--the Melbourne Longitudinal Study on Healthy Ageing (MELSHA): cross-sectional analysis of prevalence and risk factors. BMC Geriatr (2010) 0.75
Use of Biomedical Ontologies for Integration of Biological Knowledge for Learning and Prediction of Adverse Drug Reactions. Gene Regul Syst Bio (2017) 0.75
Tamoxifen-induced venothromboembolic events: exploring validation of putative genetic association. Clin Med Res (2013) 0.75
Integrating Multiple Evidence Sources to Predict Adverse Drug Reactions Based on a Systems Pharmacology Model. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discov (2017) 0.75
The Opportunities of Metabolomics in Drug Safety Evaluation. Curr Pharmacol Rep (2017) 0.75
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 32.05
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
The price of innovation: new estimates of drug development costs. J Health Econ (2003) 23.43
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell (1995) 11.62
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Drug-induced prolongation of the QT interval. N Engl J Med (2004) 10.96
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell (1995) 10.18
SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell (1995) 7.73
Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell (2004) 7.45
Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet (1996) 7.35
Statin-associated myopathy. JAMA (2003) 7.22
Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med (2002) 6.85
A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet (2006) 6.39
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature (2003) 5.94
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell (1999) 5.49
Medical genetics: a marker for Stevens-Johnson syndrome. Nature (2004) 5.43
Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J (1957) 5.29
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA (2004) 5.25
Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science (2002) 4.40
Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med (1991) 4.31
Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell (2001) 4.25
A NEW FAMILIAL CARDIAC SYNDROME IN CHILDREN. J Ir Med Assoc (1964) 3.94
Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet (1997) 3.90
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet (2002) 3.84
[RARE CARDIAC ARRYTHMIAS OF THE PEDIATRIC AGE. II. SYNCOPAL ATTACKS DUE TO PAROXYSMAL VENTRICULAR FIBRILLATION. (PRESENTATION OF 1ST CASE IN ITALIAN PEDIATRIC LITERATURE)]. Clin Pediatr (Bologna) (1963) 3.59
Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation (2006) 3.50
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet (1990) 3.38
Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation (2005) 3.31
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation (2002) 3.29
Mechanism of the cardiotoxic actions of terfenadine. JAMA (1993) 3.27
Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov (2005) 3.23
Low penetrance in the long-QT syndrome: clinical impact. Circulation (1999) 3.14
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res (1991) 3.07
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA (1993) 3.01
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov (2004) 2.96
Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve. Circulation (2005) 2.77
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation (1996) 2.70
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 2.66
Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med (2002) 2.52
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (2001) 2.49
Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology (2001) 2.40
Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation (2007) 2.38
A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A (2000) 2.26
Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther (2001) 2.25
Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation (1996) 2.18
Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet (2003) 2.18
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J (2007) 2.17
An assessment of statin safety by muscle experts. Am J Cardiol (2006) 2.16
Dispersion of repolarization in canine ventricle and the electrocardiographic T wave: Tp-e interval does not reflect transmural dispersion. Heart Rhythm (2006) 2.10
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol (2006) 2.07
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther (1998) 1.99
Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci (2003) 1.97
Genetics of acquired long QT syndrome. J Clin Invest (2005) 1.96
Electrophysiologial and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res (1970) 1.96
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J (2000) 1.92
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 1.92
Hepatic dysfunction associated with troglitazone. N Engl J Med (1998) 1.90
Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res (2005) 1.86
When good drugs go bad. Nature (2007) 1.85
A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther (2003) 1.84
A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J Clin Invest (2006) 1.79
Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut (2000) 1.78
KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation (1997) 1.76
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J (1986) 1.74
Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol (2000) 1.74
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther (2003) 1.74
Drug-induced liver injury network (DILIN). Hepatology (2004) 1.64
Combinatorial pharmacogenetics. Nat Rev Drug Discov (2005) 1.58
Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol (1983) 1.58
The efficacy of simvastatin is not influenced by CYP2D6 polymorphism. Clin Pharmacol Ther (2002) 1.51
Drug-induced liver injury: mechanisms and test systems. Hepatology (2001) 1.49
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther (2004) 1.45
Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve (2006) 1.44
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther (2004) 1.43
Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci (2001) 1.43
Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res (1985) 1.39
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics (2005) 1.38
Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol (2005) 1.38
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet (2005) 1.36
Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium. Circulation (1989) 1.32
Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology (2006) 1.31
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther (2006) 1.30
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther (2004) 1.28
The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther (2005) 1.25
Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos (2002) 1.24
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol (2006) 1.24
Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis (2003) 1.22
Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol (1990) 1.17
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol (2007) 1.16
Genetic determinants of statin intolerance. Lipids Health Dis (2007) 1.15
Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther (2002) 1.13
Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol (2005) 1.12
Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol (2005) 1.11
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics (2010) 7.07
Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet (2009) 6.79
Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet (2010) 6.44
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol (2013) 4.85
Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr (2010) 4.85
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med (2013) 4.37
Concern Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation (2002) 4.16
Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest (2006) 4.06
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 4.00
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet (2011) 3.94
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85
Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci (2010) 3.84
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet (2008) 3.61
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med (2009) 3.35
Identification of genomic predictors of atrioventricular conduction: using electronic medical records as a tool for genome science. Circulation (2010) 3.35
Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res (2002) 3.23
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol (2006) 2.94
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol (2005) 2.80
KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation (2005) 2.78
Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation (2008) 2.72
Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation (2006) 2.72
Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet (2002) 2.71
Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm (2007) 2.62
Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res (2012) 2.61
Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation (2008) 2.56
Drug-induced long QT syndrome. Pharmacol Rev (2010) 2.55
Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest (2008) 2.54
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med (2009) 2.48
Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr (2010) 2.46
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46
Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One (2010) 2.43
American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract (2003) 2.42
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol (2006) 2.41
Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A (2004) 2.41
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41
Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation (2007) 2.38
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem (2011) 2.33
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol (2005) 2.31
Unmasking of brugada syndrome by lithium. Circulation (2005) 2.30
Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res (2002) 2.28
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation (2003) 2.28
Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem (2008) 2.27
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12
Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet Med (2010) 2.09
The concentrative nucleoside transporter family, SLC28. Pflugers Arch (2003) 2.06
Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation (2013) 2.06
Differential effects of ramipril on ambulatory blood pressure in African Americans and Caucasians. Am J Hypertens (2007) 2.06
Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J (2009) 2.06
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol (2007) 2.04
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A (2003) 2.03
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood (2008) 1.99
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther (2003) 1.96
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 1.94
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat (2007) 1.92
Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm (2009) 1.92
Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet (2008) 1.89
Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. Heart Rhythm (2010) 1.87
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci U S A (2006) 1.85
When good drugs go bad. Nature (2007) 1.85
Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. J Am Coll Cardiol (2012) 1.84
Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol (2009) 1.83
A calcium sensor in the sodium channel modulates cardiac excitability. Nature (2002) 1.83